Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.20
+0.62 (7.23%)
Oct 28, 2026, 4:00 PM EDT - Market closed
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or 33.33% compared to the previous year. That makes Akari Therapeutics, the 41,210th largest employer in the world and 6,354th in the United States.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$5,160,000
Market Cap
21.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| Kyntra Bio | 34 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
| Cocrystal Pharma | 10 |
| Quoin Pharmaceuticals | 6 |
AKTX News
- 13 days ago - Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner - GlobeNewsWire
- 15 days ago - Akari Therapeutics appoints Vatnak Vat-Ho as chief business officer - TheFly
- 15 days ago - Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering - GlobeNewsWire
- 27 days ago - Akari Therapeutics expands IP portfolio with PCT filing for ADC payload - TheFly
- 27 days ago - Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers - GlobeNewsWire
- 27 days ago - Akari Therapeutics, Proxy statement: Proxy filing - Filings
- 6 weeks ago - Akari price target adjusted at Alliance Global after transfer, reverse split - TheFly
- 7 weeks ago - Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums - GlobeNewsWire